Thornwell Parker, MD
Plastic and Reconstructive Surgery · Dallas, TXNPI 1689738619
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $2,700 of the $4,493 with a category attached, or 60.1%. AbbVie accounts for 89.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $2,771 and has fallen 93.5% since, to $179 in 2025.
Across 47 payments — averaging $95.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Kerecis Limited$139
- Medical Device Business Services, Inc.$124
- Acera Surgical, Inc.$109
- Bard Peripheral Vascular, Inc.$37
- Biofrontera Inc.$37
- plus $42 from 2 others
What the payments were for
- Speaking & faculty fees$2055%
- Food & beverage$1,58935%
- Gifts$2,70060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $4,005 |
| Kerecis Limited | 1 | $139 |
| Medical Device Business Services, Inc. | 1 | $124 |
| Acera Surgical, Inc. | 1 | $109 |
| Bard Peripheral Vascular, Inc. | 1 | $37 |
| Biofrontera Inc. | 2 | $37 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $24 |
| Almirall LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,493 in reported general payments places this provider in the 60th percentile of 378 plastic and reconstructive surgery providers in Texas.
See all plastic and reconstructive surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mupirocin | 747 | $5,584 |
| Cephalexin | 274 | $2,064 |
| Fluorouracil | 16 | $1,288 |
| Metronidazole | 15 | $694 |
| Doxycycline Hyclate | 106 | $691 |
| Timolol Maleate | 36 | $505 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $99 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $58 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Dallas
- Ben TittleDallas$73K
- Jennifer KargelDallas$17K
- Richard HaDallas$17K
- Solomon AzouzDallas$16K
- Bradley HubbardDallas$14K
- Jeffrey KenkelDallas$12K
- Aldona SpiegelHouston$759K
- Charles ButlerHouston$227K
- Michael KlebucHouston$204K
- Joshua LemmonRichardson$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.